Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV vaccine effectiveness study in MSM attending the Amsterdam sexual health clinic
NL-OMON60399Phase 4Active, not recruiting
- Sponsor
- Public Health Service of Amsterdam
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection (2 cohorts), sponsored by Public Health Service of Amsterdam. Started Feb 2023; status: active, not recruiting.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NL-OMON60399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60399.